S&P 500   4,484.61 (+0.30%)
DOW   35,245.62 (-0.14%)
QQQ   372.54 (+0.98%)
AAPL   146.69 (+1.28%)
MSFT   307.19 (+0.98%)
FB   334.35 (+2.95%)
GOOGL   2,849.07 (+0.77%)
TSLA   873.39 (+3.60%)
AMZN   3,447.21 (+1.12%)
NVDA   222.81 (+1.92%)
BABA   167.67 (-0.20%)
NIO   39.69 (+5.25%)
CGC   13.21 (-1.05%)
GE   104.10 (-0.30%)
MU   67.19 (-0.72%)
AMD   116.62 (+4.01%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.93 (-1.42%)
DIS   170.60 (-3.32%)
PFE   41.36 (-0.31%)
BA   216.04 (-0.46%)
AMC   42.99 (+5.52%)
S&P 500   4,484.61 (+0.30%)
DOW   35,245.62 (-0.14%)
QQQ   372.54 (+0.98%)
AAPL   146.69 (+1.28%)
MSFT   307.19 (+0.98%)
FB   334.35 (+2.95%)
GOOGL   2,849.07 (+0.77%)
TSLA   873.39 (+3.60%)
AMZN   3,447.21 (+1.12%)
NVDA   222.81 (+1.92%)
BABA   167.67 (-0.20%)
NIO   39.69 (+5.25%)
CGC   13.21 (-1.05%)
GE   104.10 (-0.30%)
MU   67.19 (-0.72%)
AMD   116.62 (+4.01%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.93 (-1.42%)
DIS   170.60 (-3.32%)
PFE   41.36 (-0.31%)
BA   216.04 (-0.46%)
AMC   42.99 (+5.52%)
S&P 500   4,484.61 (+0.30%)
DOW   35,245.62 (-0.14%)
QQQ   372.54 (+0.98%)
AAPL   146.69 (+1.28%)
MSFT   307.19 (+0.98%)
FB   334.35 (+2.95%)
GOOGL   2,849.07 (+0.77%)
TSLA   873.39 (+3.60%)
AMZN   3,447.21 (+1.12%)
NVDA   222.81 (+1.92%)
BABA   167.67 (-0.20%)
NIO   39.69 (+5.25%)
CGC   13.21 (-1.05%)
GE   104.10 (-0.30%)
MU   67.19 (-0.72%)
AMD   116.62 (+4.01%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.93 (-1.42%)
DIS   170.60 (-3.32%)
PFE   41.36 (-0.31%)
BA   216.04 (-0.46%)
AMC   42.99 (+5.52%)
S&P 500   4,484.61 (+0.30%)
DOW   35,245.62 (-0.14%)
QQQ   372.54 (+0.98%)
AAPL   146.69 (+1.28%)
MSFT   307.19 (+0.98%)
FB   334.35 (+2.95%)
GOOGL   2,849.07 (+0.77%)
TSLA   873.39 (+3.60%)
AMZN   3,447.21 (+1.12%)
NVDA   222.81 (+1.92%)
BABA   167.67 (-0.20%)
NIO   39.69 (+5.25%)
CGC   13.21 (-1.05%)
GE   104.10 (-0.30%)
MU   67.19 (-0.72%)
AMD   116.62 (+4.01%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.93 (-1.42%)
DIS   170.60 (-3.32%)
PFE   41.36 (-0.31%)
BA   216.04 (-0.46%)
AMC   42.99 (+5.52%)
NYSE:AMAM

Ambrx Biopharma Stock Forecast, Price & News

$12.77
+0.30 (+2.41 %)
(As of 10/18/2021 02:30 PM ET)
Add
Compare
Today's Range
$12.75
$13.34
50-Day Range
$11.10
$18.70
52-Week Range
$11.03
$22.87
Volume891 shs
Average Volume30,590 shs
Market Capitalization$481.03 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AMAM News and Ratings via Email

Sign-up to receive the latest news and ratings for Ambrx Biopharma and its competitors with MarketBeat's FREE daily newsletter.


About Ambrx Biopharma

Ambrx Biopharma Inc., a clinical-stage biologics company, focuses on discovering and developing engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 ADC, which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction (GEJ) cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug (IND)-enabling studies for the treatment of renal cell carcinoma (RCC) and other cancers, as well as other multiple product candidates targeting immuno-oncology applications. In addition, it is developing ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the à and gamma receptors on the cytotoxic T cell; and ARX822, a fab-small molecule bispecific that is in preclinical development for cancers. The company has license agreements with NovoCodex, Bristol Myers Squibb Company, Agensys, Inc., Sino Biopharmaceutical Co., Ltd., University of California, BeiGene, Ltd., The Scripps Research Institute and The California Research Institute of Biomedical Research, AbbVie Inc., Astellas Pharma Inc., and Elanco Animal Health. Ambrx Biopharma Inc. was founded in 2003 and is based in La Jolla, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Employees
70
Year Founded
N/A

Sales & Book Value

Annual Sales
$13.67 million

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$481.03 million
Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

900th out of 1,361 stocks

Biological Products, Except Diagnostic Industry

137th out of 196 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Ambrx Biopharma (NYSE:AMAM) Frequently Asked Questions

Is Ambrx Biopharma a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ambrx Biopharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ambrx Biopharma stock.
View analyst ratings for Ambrx Biopharma
or view top-rated stocks.

What stocks does MarketBeat like better than Ambrx Biopharma?

Wall Street analysts have given Ambrx Biopharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ambrx Biopharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Ambrx Biopharma?

Ambrx Biopharma saw a increase in short interest during the month of September. As of September 30th, there was short interest totaling 12,700 shares, an increase of 154.0% from the September 15th total of 5,000 shares. Based on an average daily trading volume, of 26,000 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.0% of the shares of the stock are short sold.
View Ambrx Biopharma's Short Interest
.

What price target have analysts set for AMAM?

3 brokers have issued twelve-month price targets for Ambrx Biopharma's shares. Their forecasts range from $21.30 to $53.00. On average, they anticipate Ambrx Biopharma's share price to reach $33.43 in the next twelve months. This suggests a possible upside of 161.8% from the stock's current price.
View analysts' price targets for Ambrx Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Ambrx Biopharma's key executives?

Ambrx Biopharma's management team includes the following people:
  • Dr. Feng Tian, Pres, CEO & Chairman (Age 53)
  • Ms. Yumei Zhang CPA, M.B.A., VP of Fin.
  • Dr. Joy Yan M.D., Ph.D., Chief Medical Officer (Age 41)
  • Mr. Simon J. Allen B.Sc., M.B.A., MBA, Chief Bus. Officer (Age 53)
  • Dr. Sukumar Sakamuri Ph.D., VP & Head of Chemistry
  • Dr. Shawn Shao-Hui Zhang, Sr. VP of R&D Operations and Ambrx China

When did Ambrx Biopharma IPO?

(AMAM) raised $126 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs, BofA Securities and Cowen acted as the underwriters for the IPO.

What is Ambrx Biopharma's stock symbol?

Ambrx Biopharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMAM."

When does Ambrx Biopharma's lock-up period expire?

Ambrx Biopharma's lock-up period expires on Wednesday, December 15th. Ambrx Biopharma had issued 7,000,000 shares in its initial public offering on June 18th. The total size of the offering was $126,000,000 based on an initial share price of $18.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

How do I buy shares of Ambrx Biopharma?

Shares of AMAM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ambrx Biopharma's stock price today?

One share of AMAM stock can currently be purchased for approximately $12.77.

How much money does Ambrx Biopharma make?

Ambrx Biopharma has a market capitalization of $481.03 million and generates $13.67 million in revenue each year.

How many employees does Ambrx Biopharma have?

Ambrx Biopharma employs 70 workers across the globe.

What is Ambrx Biopharma's official website?

The official website for Ambrx Biopharma is ambrx.com.

How can I contact Ambrx Biopharma?

The company can be reached via phone at 858-729-3339.


This page was last updated on 10/18/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.